Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 13.16 |
| Open | 13.18 |
| Bid | 0.00 x 3200 |
| Ask | 0.00 x 4000 |
| Day's Range | 13.17 - 13.26 |
| 52 Week Range | 13.11 - 17.11 |
| Volume | |
| Avg. Volume | 1,865,445 |
| Market Cap | 41.816B |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | 36.78 |
| EPS (TTM) | 0.36 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.64 (4.85%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | 18.40 |
Barrons.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.
Business WireU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to
Business WireTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
CAMBRIDGE, Mass., April 08, 2024--Takeda (TSE:4502/NYSE:TAK) today announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility (CSR) program. To create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of Food is Health and Building STEM (Science, Technology, Engineering and Math) Foundations and p
